Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | complement component 5a receptor 1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus multilocularis | G-protein coupled receptor, putative | complement component 5a receptor 1 | 350 aa | 293 aa | 22.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | serine/threonine protein kinase KIN, putative | 0.0012 | 0 | 0.5 |
Brugia malayi | cyclin-dependent kinase 9 | 0.0049 | 0.0959 | 0.0959 |
Entamoeba histolytica | protein kinase domain containing protein | 0.0049 | 0.0959 | 1 |
Onchocerca volvulus | 0.0403 | 1 | 0.5 | |
Echinococcus multilocularis | cyclin dependent kinase 9 | 0.0049 | 0.0959 | 0.0959 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0403 | 1 | 1 |
Echinococcus granulosus | cyclin dependent kinase 9 | 0.0057 | 0.1162 | 0.1162 |
Plasmodium vivax | cyclin dependent kinase 7 (cdk7), putative | 0.0012 | 0 | 0.5 |
Plasmodium falciparum | MO15-related protein kinase | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0403 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0403 | 1 | 1 |
Echinococcus granulosus | CDC7 cell division cycle 7 | 0.0403 | 1 | 1 |
Schistosoma mansoni | kinase | 0.0049 | 0.0959 | 0.0959 |
Echinococcus multilocularis | CDC7 cell division cycle 7 | 0.0403 | 1 | 1 |
Leishmania major | serine/threonine kinase-like protein, putative | 0.0012 | 0 | 0.5 |
Trypanosoma brucei | Mitogen-activated protein kinase 10, putative | 0.0012 | 0 | 0.5 |
Trypanosoma cruzi | Mitogen-activated protein kinase 10, putative | 0.0012 | 0 | 0.5 |
Trypanosoma brucei | protein kinase, putative | 0.0012 | 0 | 0.5 |
Giardia lamblia | Kinase, CDC7 | 0.0403 | 1 | 1 |
Onchocerca volvulus | 0.0403 | 1 | 0.5 | |
Echinococcus multilocularis | cyclin dependent kinase 9 | 0.0057 | 0.1162 | 0.1162 |
Echinococcus granulosus | cyclin dependent kinase 9 | 0.0049 | 0.0959 | 0.0959 |
Trypanosoma cruzi | Mitogen-activated protein kinase 10, putative | 0.0012 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0258 | 0.6315 | 0.6315 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0049 | 0.0959 | 0.0959 |
Leishmania major | mitogen-activated protein kinase, putative,map kinase-like protein | 0.0012 | 0 | 0.5 |
Loa Loa (eye worm) | CDC7 protein kinase | 0.0403 | 1 | 1 |
Trypanosoma cruzi | serine/threonine protein kinase, putative | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0403 | 1 | 1 |
Loa Loa (eye worm) | CMGC/CDK/CDK9 protein kinase | 0.0049 | 0.0959 | 0.0959 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.45 uM | Tested for the ability to compete with [125I]-CO13 ([125I]-Y-F-K-A-Cha-G-L-dF-R) for binding to C5a anaphylatoxin chemotactic receptor from human neutrophil membrane preparations | ChEMBL. | No reference |
IC50 (binding) | = 0.45 uM | Tested for the ability to compete with [125I]-CO13 ([125I]-Y-F-K-A-Cha-G-L-dF-R) for binding to C5a anaphylatoxin chemotactic receptor from human neutrophil membrane preparations | ChEMBL. | No reference |
IC50 (binding) | = 5 uM | Tested for its ability to compete with [125I]-C5a for binding to C5a anaphylatoxin chemotactic receptor of human neutrophil membrane preparations | ChEMBL. | No reference |
IC50 (binding) | = 5 uM | Tested for its ability to compete with [125I]-C5a for binding to C5a anaphylatoxin chemotactic receptor of human neutrophil membrane preparations | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.